我们通过实时检索，整理了近期围绕 Oric Pharmaceuticals, Inc.（ORIC）人工智能布局的公开报道与信息。以下内容均摘自可核实的来源链接，供读者交叉验证。
ORIC Pharmaceuticals, Inc. develops innovative cancer therapies. Key candidates include ORIC-114 targeting brain cancers and ORIC-944 for prostate cancer, both in Phase 1b trials. ... ORIC (ORIC) has an AI Score of -/10 () because, according to an overall anal…
来源：ORIC Pharmaceuticals Inc (ORIC) Stock AI Rating &
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer · The owner of this website has made a commitment to accessibil…
来源：HOME - ORIC Pharmaceuticals
SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ -- OpenBench, Inc., a pioneer in AI-enabled success-driven small molecule discovery partnerships, today announced the launch of a collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology…
来源：OpenBench and ORIC Pharmaceuticals Launch Success-
客观分析
ORIC Pharmaceuticals是一家专注于开发创新癌症疗法的生物制药公司，其核心在研药物包括针对脑癌的ORIC-114和针对前列腺癌的ORIC-944，均处于1b期临床试验阶段。公司已启动 Himalayas-1 三期临床试验，评估 Rinzimetostat 联合拜耳 NUBEQA 治疗转移性去势抵抗性前列腺癌（mCRPC）的效果。此外，ORIC 与 AI 药物发现公司 OpenBench 达成合作，探索AI驱动的成功导向型小分子发现。报道显示，ORIC 在AI评分系统中获得负分（-/10），表明其当前AI市场表现或评级偏弱。